Lack of Association between Serum Adiponectin/Leptin Levels and Medullary Thyroid Cancer

  • Abooshahab, Raziyeh (Department of Biology, Faculty of Basic Sciences, Science Research Campus of Islamic Azad University) ;
  • Yaghmaei, Parichehr (Department of Biology, Faculty of Basic Sciences, Science Research Campus of Islamic Azad University) ;
  • Ghadaksaz, Hoda Gholab (Cellular and Molecular Research Centre, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences) ;
  • Hedayati, Mehdi (Cellular and Molecular Research Centre, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences)
  • Published : 2016.08.01


Background: Adipokines are bioactive proteins that mediate metabolism, inflammation and angiogenesis. Changes in the secretion of key serum adipokines - adiponectin and letpin - may be associated with obesity, cancer and metabolic disorders. Thyroid cancer is one of the most important types of endocrine cancer. Therefore, investigating the association between serum levels of adiponectin and leptin and thyroid cancer might be important. The purpose of this study was to assess adiponectin and leptin levels in medullary thyroid carcinoma (MTC) cases in order to identify novel tumor markers. Materials and Methods: This research was based on a case-control study, including 45 patients with medullary thyroid cancer (21 men and 24 women) and 45 healthy controls (24 males and 21 females). Adiponectin and leptin levels were measured by ELISA in both groups. Height and weight were measured and body mass index (kg/m2) was calculated. Results: Adiponectin and leptin levels were not significantly different between medullary thyroid carcinomas and the control group. Also, there was no correlation among age and body mass index and the disease. Conclusions: These results suggest that changes in serum adiponectin and leptin levels do not play an important role in the diagnosis or could act as as biomarkers for medullary thyroid cancer.


Supported by : Endocrine Research Center, Shahid Beheshti University of Medical Sciences


  1. Ahima R, Flier J (2000). Adipose tissue as an endocrine organ. Trends Endocrinol Metabolism, 11, 327-32.
  2. Ahima R (2006). Adipose tissue as an endocrine organ. Obesity, 14, 242-9.
  3. Akinci M, Kosova F, Cetin B, et al (2009). Leptin levels in thyroid cancer. Asian J Surg, 32, 216-23.
  4. Banks A (2000). Activation of downstream signals by the long form of the leptin receptor. J Biological Chemistry, 275, 14563-72.
  5. Barb D, Williams C, Neuwirth A, Mantzoros C (2007). Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr, 86, 858-66.
  6. Baratta M (2002). Leptin-from a signal of adiposity to a hormonal mediator in peripheral tissues. Med Sci Monit, 8, 282-92.
  7. Berg A, Combs T, Scherer P (2002). ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends in Endocrinol Metabolism, 13, 84-9.
  8. Booth A, Magnuson A, Fouts J, Foster M (2015). Adipose tissue, obesity and adipokines: role in cancer promotion. Hormone Molecular Biol Clin Investigat.
  9. Bub J, Miyazaki T, Iwamoto Y (2006). Adiponectin as a growth inhibitor in prostate cancer. Biophys Res Commun, 340, 1158-66.
  10. Cheng S, Chi C, Tzen C, et al (2010). Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma. Surgery, 147, 847-53.
  11. Danese E, Minicozzi AM, Montagnana M, et al (2013). Lack of an Association between circulating adiponectin levels and risk of colorectal adenoma. Clinical Laboratory.
  12. Di Cristofano A (2013). Obesity and thyroid cancer: Is Leptin the (Only) Link? Endocrinol, 154, 2567-9.
  13. Fruhbeck G (2006). Intracellular signalling pathways activated by leptin. Biochem J, 393, 7-20.
  14. Griebeler M, Gharib H, Thompson G (2013). Medullary thyroid carcinoma. Endocrine Practice, 19, 703-11.
  15. Hedayati M, Zarif Yeganeh M, Sheikhol Eslami S, et al (2011). Predominant RET germline mutations in exons 10, 11, and 16 in iranian patients with hereditary medullary thyroid carcinoma. J Thyroid Res, 2011, 1-6.
  16. Hedayati M, Nabipour I, Rezaei-Ghaleh N, Azizi F (2006). Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases. Med J Malaysia, 61, 564-9.
  17. Hedayati M, Yeganeh M, Sheikholeslami S, Azizi F (2015). Wide screening of RET proto-oncogene in Iranian medullary thyroid carcinoma patients: 13 years study. Endocrine Abstracts.
  18. Hedayati M, Yaghmaei P, Pooyamanesh Z, et al (2011). Leptin: A Correlated Peptide to Papillary Thyroid Carcinoma? J Thyroid Res, 2011, 1-5.
  19. Howard J, Pidgeon G, Reynolds J (2010). Leptin and gastrointestinal malignancies. Obesity Rev, 11, 863-74.
  20. Kadowaki T, Yamauchi T (2005). Adiponectin and Adiponectin Receptors. Endocrine Rev, 26, 439-51.
  21. Kaklamani V, Wisinski K, Sadim M, et al (2008). Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA, 300, 1523-31
  22. Kim A, Lee Y, Kim K, et al(2010). Adiponectin Represses Colon Cancer Cell Proliferation via AdipoR1- and -R2-Mediated AMPK Activation. Molecular Endocrinol, 24, 1441-52.
  23. Liang J, Zubovitz J, Petrocelli T, et al (2002). PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nature Med, 8, 1153-60.
  24. Mandal P, Pratt B, Barnes M, et al (2011). Molecular mechanism for Adiponectin-dependent M2 macrophage polarization: link between the metabolic and innate immune activity of full-length adiponectin. J Biological Chem, 286, 13460-9.
  25. Mitsiades N, Pazaitou-Panayiotou K, Aronis K, et al (2011). Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies. J Clin Endocrinol Metabolism, 96, 2023-8.
  26. Otvos L, Haspinger E, La Russa F, et al (2011). Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol, 11, 90.
  27. Paz-Filho G (2011). Associations between adipokines and obesity-related cancer. Frontiers Bioscience, 16, 1634.
  28. Park J, Euhus D, Scherer P (2011). Paracrine and Endocrine Effects of Adipose Tissue on Cancer Development and Progression. Endocrine Rev, 32, 550-70.
  29. Peso L (1997). Interleukin-3-induced phosphorylation of BAD through the Protein Kinase Akt. Science, 278, 687-9.
  30. Pezzilli R, Barassi A, Corsi M, et al (2010) Serum leptin, but not adiponectin and receptor for advanced glycation end products, is able to distinguish autoimmune pancreatitis from both chronic pancreatitis and pancreatic neoplasms. Scandinavian J Gastroenterol, 45, 93-9.
  31. Pontikides N, Krassas G (2007). Basic endocrine products of adipose tissue in states of thyroid dysfunction. Thyroid, 17, 421-31.
  32. Segev D, Umbricht C, Zeiger M (2003). Molecular pathogenesis of thyroid cancer. Surgical Oncol, 12, 69-90.
  33. Stevens V, Jacobs E, Sun J, Gapstur S (2014). No association of plasma levels of adiponectin and c-peptide with risk of aggressive prostate cancer in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev, 23, 890-2.
  34. Tworoger S, Eliassen A, Kelesidis T, et al (2007). Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metabolism, 92, 1510-6.
  35. Uddin S, Bu R, Ahmed M, et al (2010). Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma. Leukemia Lymphoma, 51, 1305-14